Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Jeffrey

Showing results (461-470 of 651) with videos related to

Pageof 66
Sort By:
ACS Chemical Neuroscience|September 20, 2011
(3-Cyano-5-fluorophenyl)biaryl negative allosteric modulators of mGlu(5): Discovery of a new tool compound with activity in the OSS mouse model of addictionCraig W Lindsley, Brittney S Bates, Usha N Menon, et al.
Bioorganic & Medicinal Chemistry Letters|October 13, 2022
Discovery of a potent M<sub>5</sub> antagonist with improved clearance profile. Part 2: Pyrrolidine amide-based antagonistsDouglas L Orsi, Andrew S Felts, Alice L Rodriguez, et al.
ACS Medicinal Chemistry Letters|January 12, 2013
Discovery of N-Aryl Piperazines as Selective mGlu(5) Potentiators with Efficacy in a Rodent Model Predictive of Anti-Psychotic ActivityYa Zhou, Jason T Manka, Alice L Rodriguez, et al.
Research Square|April 16, 2025
Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of the Muscarinic M 1 Positive Allosteric Modulator VU0467319 for Alzheimer's disease: A Single Ascending-Dose Study in Healthy ParticipantsAlexander C Conley, Alexandra P Key, Jennifer U Blackford, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|November 4, 2008
Toward an improved prediction of human in vivo brain penetrationS G Summerfield, A J Lucas, R A Porter, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|April 4, 2020
Bile acids associate with specific gut microbiota, low-level alcohol consumption and liver fibrosis in patients with non-alcoholic fatty liver diseaseLeon A Adams, Zhengyi Wang, Chris Liddle, et al.
Alzheimer'S Research & Therapy|July 2, 2025
Safety, tolerability, pharmacokinetic and pharmacodynamic effects of the muscarinic M<sub>1</sub> positive allosteric modulator VU0467319 for Alzheimer's disease: a single ascending-dose study in healthy participantsAlexander C Conley, Alexandra P Key, Jennifer U Blackford, et al.
Pain|April 27, 2001
Orexin-A, an hypothalamic peptide with analgesic propertiesS Bingham, P T Davey, A J Babbs, et al.
Bioorganic & Medicinal Chemistry Letters|December 3, 2019
Discovery of structurally distinct tricyclic M<sub>4</sub> positive allosteric modulator (PAM) chemotypesKayla J Temple, Madeline F Long, Julie L Engers, et al.
Bioorganic & Medicinal Chemistry Letters|January 28, 2014
Novel GlyT1 inhibitor chemotypes by scaffold hopping. Part 2: development of a [3.3.0]-based series and other piperidine bioisosteresDouglas J Sheffler, Michael T Nedelcovych, Richard Williams, et al.
Pageof 66

Showing results (461-470 of 651) with videos related to

Sort By:
Pageof 66
ACS Chemical Neuroscience|September 20, 2011
(3-Cyano-5-fluorophenyl)biaryl negative allosteric modulators of mGlu(5): Discovery of a new tool compound with activity in the OSS mouse model of addictionCraig W Lindsley, Brittney S Bates, Usha N Menon, et al.
Bioorganic & Medicinal Chemistry Letters|October 13, 2022
Discovery of a potent M<sub>5</sub> antagonist with improved clearance profile. Part 2: Pyrrolidine amide-based antagonistsDouglas L Orsi, Andrew S Felts, Alice L Rodriguez, et al.
ACS Medicinal Chemistry Letters|January 12, 2013
Discovery of N-Aryl Piperazines as Selective mGlu(5) Potentiators with Efficacy in a Rodent Model Predictive of Anti-Psychotic ActivityYa Zhou, Jason T Manka, Alice L Rodriguez, et al.
Research Square|April 16, 2025
Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of the Muscarinic M 1 Positive Allosteric Modulator VU0467319 for Alzheimer's disease: A Single Ascending-Dose Study in Healthy ParticipantsAlexander C Conley, Alexandra P Key, Jennifer U Blackford, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|November 4, 2008
Toward an improved prediction of human in vivo brain penetrationS G Summerfield, A J Lucas, R A Porter, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|April 4, 2020
Bile acids associate with specific gut microbiota, low-level alcohol consumption and liver fibrosis in patients with non-alcoholic fatty liver diseaseLeon A Adams, Zhengyi Wang, Chris Liddle, et al.
Alzheimer'S Research & Therapy|July 2, 2025
Safety, tolerability, pharmacokinetic and pharmacodynamic effects of the muscarinic M<sub>1</sub> positive allosteric modulator VU0467319 for Alzheimer's disease: a single ascending-dose study in healthy participantsAlexander C Conley, Alexandra P Key, Jennifer U Blackford, et al.
Pain|April 27, 2001
Orexin-A, an hypothalamic peptide with analgesic propertiesS Bingham, P T Davey, A J Babbs, et al.
Bioorganic & Medicinal Chemistry Letters|December 3, 2019
Discovery of structurally distinct tricyclic M<sub>4</sub> positive allosteric modulator (PAM) chemotypesKayla J Temple, Madeline F Long, Julie L Engers, et al.
Bioorganic & Medicinal Chemistry Letters|January 28, 2014
Novel GlyT1 inhibitor chemotypes by scaffold hopping. Part 2: development of a [3.3.0]-based series and other piperidine bioisosteresDouglas J Sheffler, Michael T Nedelcovych, Richard Williams, et al.
Pageof 66